Nasus Pharma (NSRX) vs Veru (VERU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Veru (VERU) has outperformed Nasus Pharma (NSRX) over the past year, losing 45.1% versus a loss of 50.1%. Nasus Pharma is the larger company by market cap ($42.5 million vs $41.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NSRX | VERU |
|---|---|---|
| Share price | $3.63 | $2.42 |
| Market cap | $42.52M | $41.26M |
| 1-day change | -3.84% | -1.63% |
| YTD return | -60.33% | +13.08% |
| 1-year return | -50.07% | -45.12% |
| 5-year return | — | -97.18% |
| EPS (TTM) | $-1.20 | $-0.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.50 | $7.33 |
| 52-week low | $1.98 | $2.05 |
| Distance from 52-week high | -61.79% | -66.98% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +441.87% | +960.74% |
| Average volume | 16.09K | 242.06K |
| Shares outstanding | 11.71M | 17.05M |
| Employees | 7 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Nasus Pharma
NSRX stock →Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Veru
VERU stock →Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
NSRX vs VERU FAQ
Which is bigger, Nasus Pharma or Veru?
Nasus Pharma (NSRX) is larger, with a market capitalization of $42.52M compared with $41.26M for Veru (VERU).
Which stock has performed better over the past year, NSRX or VERU?
VERU returned -45.12% over the past 12 months, compared with -50.07% for NSRX (price return, excluding dividends). Past performance does not predict future results.
Are Nasus Pharma and Veru in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.